Future Planet Capital

HALO X-ray Technologies has been spun out of the Imaging Science Group at Nottingham Trent University and the Cranfield Forensic Institute at Cranfield University. We are developing commercially-focused OEM X-ray diffraction solutions based on novel and patented Focal Construct Technology that provides platform capability across a wide range of application areas. Their initial focus lies in the development of HALO solutions for the aviation security and the medical systems markets. We have strong ties to the aviation sector through a long and prestigious research and development programme that has previously realised novel divergent beam X-ray technology (developed and marketed through various incumbent suppliers such as 3DX-ray Ltd) and kinetic depth systems (developed and marketed through Astrophyscis Inc) as 3rd party solutions. We have a clear focus on medical systems and we are currently part of a consortium recentlly awarded an EPSRC grant on Point-of-Care High Accuracy Fracture Risk Prediction. This is an exciting project and we look forward to working with our partners in developing HALO technology for this market.

CHAIN Biotechnology Ltd. is a biotechnology company based in London, United Kingdom, that specializes in harnessing Clostridium bacteria for various applications. Founded in 2014, the company focuses on advancing fermentation processes through synthetic biology and automation, particularly utilizing Clostridium strains to produce chiral chemicals. These chemicals are incorporated into a range of products, including nutraceuticals, personal healthcare items, pharmaceuticals, and fragrances. Notable developments include 3-hydroxybutyrate and (R)-methyl-3HB, a precursor used in glaucoma treatment. CHAIN Biotechnology also aims to create cost-effective fermentation routes from sugar. In addition to its work in fermentation, the company is exploring microbiome therapeutics, developing novel compounds aimed at treating chronic gut-related diseases using its proprietary drug development platform.

iEthico specializes in digital technology for streamlining pharmaceutical sourcing. Its automated cloud-based service tracks data, alerts users to medicine shortages, and connects them to reliable sources. The MHRA-approved platform also automates regulatory processes, saving pharmacies time and effort. After successful market testing, the solution is now being rolled out nationwide across community and NHS Trusts in the UK.

Glycoscoredx specializes in diagnostic solutions for prostate cancer, offering a blood test that utilizes a unique combination of biomarkers to accurately identify clinically significant cases of the disease. This innovative approach helps reduce the incidence of late diagnoses and minimizes unnecessary invasive procedures, such as prostate-tissue biopsies, by ruling out cancer in many patients. By delivering reliable testing options, Glycoscoredx aims to enhance patient outcomes and support early detection efforts, thus enabling healthcare providers to focus on individuals at a higher risk for aggressive prostate cancer. The company addresses customer inquiries through various channels, including phone, email, and online applications.

iFAST is addressing the Antimicrobial Susceptibility Testing market, reducing the spread of antimicrobial resistance.

iEthico specializes in digital technology for streamlining pharmaceutical sourcing. Its automated cloud-based service tracks data, alerts users to medicine shortages, and connects them to reliable sources. The MHRA-approved platform also automates regulatory processes, saving pharmacies time and effort. After successful market testing, the solution is now being rolled out nationwide across community and NHS Trusts in the UK.

Eyoto is a technology company focused on transforming eye care delivery through innovative tele-optometry solutions. It specializes in developing software services that include image processing, computer vision, eye-tracking, and artificial intelligence. The company offers a cloud-connected platform that enhances the efficiency of eye care practices by providing rapid power mapping and visualization of lenses. This platform allows for evidence-based dispensing experiences, facilitating improved accuracy and portability in ocular care. By leveraging its advanced technology, Eyoto aims to create a comprehensive ocular care ecosystem, making eye care more accessible and cost-effective for businesses and patients alike.

AMLo Biosciences Ltd is a biotechnology company based in Newcastle upon Tyne, United Kingdom, focused on developing diagnostic solutions for melanoma. Incorporated in 2017, the company has created a diagnostic kit that utilizes the AMBLor test, which accurately predicts the risk of disease progression in patients with early AJCC Stage I and Stage II melanoma. This test identifies two specific proteins in the skin overlying the primary tumor that are typically lost in high-risk melanoma cases. By providing a reliable prognostic assessment, AMLo aims to help stratify patients for appropriate treatment and follow-up, ultimately reducing the psychological burden on patients and decreasing healthcare costs associated with unnecessary surveillance.

Phoenix Health & Safety specializes in delivering health and safety training courses that are accredited by recognized organizations such as IOSH, NEBOSH, ConstructionSkills, and CIEH. The company focuses on providing comprehensive training for individuals responsible for managing health and safety in various settings. Its offerings include both in-person and online courses, which lead to certifications and diplomas. Additionally, Phoenix Health & Safety provides first aid training and electronic learning opportunities, ensuring that students receive relevant qualifications to enhance their career prospects in the health sector. The company boasts a strong commitment to its training effectiveness, guaranteeing a pass for all participants in IOSH and NEBOSH courses.

MicrofluidX Ltd is a London-based company established in 2018 that specializes in developing a cell bioprocessing platform specifically designed for autologous cell and gene therapy manufacturing. The company offers a microfluidic bioprocessing system that integrates various cell culture capabilities—including seeding, expansion, differentiation, transduction, washing, sorting, concentration, sampling, and harvesting—into a single closed system. This automated technology addresses key challenges in the field, such as process control, scalability, and cost, enabling biologists to efficiently conduct process development by experimenting with multiple cell culture conditions.

Presymptom Health is a medical technology company dedicated to advancing healthcare through the development of pre-symptomatic diagnostic tests and clinical decision support algorithms. The company focuses on creating innovative blood tests designed to detect illnesses at an early stage, particularly aiming to predict the onset of sepsis up to three days before symptoms manifest. By enabling earlier intervention, Presymptom Health seeks to improve critical care outcomes and enhance patient management, ultimately contributing to better survival rates and healthcare efficiency.

AgPlus Diagnostics Ltd. is a UK-based company specializing in the development of diagnostic platform technology aimed at providing quantitative point-of-care (PoC) testing solutions for various clinical applications, including both human and veterinary diagnostics. Founded in 2009 and headquartered in Sharnbrook, the company designs, manufactures, and supplies diagnostic tests and associated readers. AgPlus Diagnostics focuses on creating portable diagnostic devices that utilize electrochemical signaling and measurement systems, enabling healthcare providers to deliver personalized care through rapid and accurate testing. This innovative approach facilitates timely diagnostic results, allowing healthcare professionals to make critical treatment decisions quickly, ultimately benefiting patient outcomes.

Glycoscoredx specializes in diagnostic solutions for prostate cancer, offering a blood test that utilizes a unique combination of biomarkers to accurately identify clinically significant cases of the disease. This innovative approach helps reduce the incidence of late diagnoses and minimizes unnecessary invasive procedures, such as prostate-tissue biopsies, by ruling out cancer in many patients. By delivering reliable testing options, Glycoscoredx aims to enhance patient outcomes and support early detection efforts, thus enabling healthcare providers to focus on individuals at a higher risk for aggressive prostate cancer. The company addresses customer inquiries through various channels, including phone, email, and online applications.

HALO X-ray Technologies has been spun out of the Imaging Science Group at Nottingham Trent University and the Cranfield Forensic Institute at Cranfield University. We are developing commercially-focused OEM X-ray diffraction solutions based on novel and patented Focal Construct Technology that provides platform capability across a wide range of application areas. Their initial focus lies in the development of HALO solutions for the aviation security and the medical systems markets. We have strong ties to the aviation sector through a long and prestigious research and development programme that has previously realised novel divergent beam X-ray technology (developed and marketed through various incumbent suppliers such as 3DX-ray Ltd) and kinetic depth systems (developed and marketed through Astrophyscis Inc) as 3rd party solutions. We have a clear focus on medical systems and we are currently part of a consortium recentlly awarded an EPSRC grant on Point-of-Care High Accuracy Fracture Risk Prediction. This is an exciting project and we look forward to working with our partners in developing HALO technology for this market.

Linear Diagnostics develops a proprietary diagnostic platform technology that enables rapid, simultaneous detection of multiple targets using a single reagent. Its core innovation, linear dichroism, facilitates molecular diagnostics tests across various sectors, including infectious diseases and food safety.

Congenica Ltd. is a biotechnology company that specializes in clinical data solutions for genetic diagnosis. Established in 2012 and headquartered in Hinxton, United Kingdom, it offers the Sapientia platform, a clinical genomic analytics tool that integrates human DNA sequences with deep clinical phenotyping. This platform enables clinicians and researchers to interpret genetic diseases and provides actionable insights for diagnosis, prognosis, and research. Additionally, Sapientia supports personalized medicine by facilitating the creation of disease registries, identifying patient populations for clinical studies, and aiding in the discovery of novel drug targets and biomarkers. Congenica's focus is on improving clinical outcomes through advanced genomic analysis.

AMLo Biosciences Ltd is a biotechnology company based in Newcastle upon Tyne, United Kingdom, focused on developing diagnostic solutions for melanoma. Incorporated in 2017, the company has created a diagnostic kit that utilizes the AMBLor test, which accurately predicts the risk of disease progression in patients with early AJCC Stage I and Stage II melanoma. This test identifies two specific proteins in the skin overlying the primary tumor that are typically lost in high-risk melanoma cases. By providing a reliable prognostic assessment, AMLo aims to help stratify patients for appropriate treatment and follow-up, ultimately reducing the psychological burden on patients and decreasing healthcare costs associated with unnecessary surveillance.

AgPlus Diagnostics Ltd. is a UK-based company specializing in the development of diagnostic platform technology aimed at providing quantitative point-of-care (PoC) testing solutions for various clinical applications, including both human and veterinary diagnostics. Founded in 2009 and headquartered in Sharnbrook, the company designs, manufactures, and supplies diagnostic tests and associated readers. AgPlus Diagnostics focuses on creating portable diagnostic devices that utilize electrochemical signaling and measurement systems, enabling healthcare providers to deliver personalized care through rapid and accurate testing. This innovative approach facilitates timely diagnostic results, allowing healthcare professionals to make critical treatment decisions quickly, ultimately benefiting patient outcomes.

Attomarker is a pioneering health tech company spun out from the University of Exeter. Led by Professor Andrew Shaw, it specializes in patented nanophotonic technology for multiplexed blood testing. The company's flagship product is a CE-marked platform offering rapid, accurate diagnostics via a mobile device, initially focusing on food allergens, pregnancy tests, and infection markers like C-reactive protein.

MicrofluidX Ltd is a London-based company established in 2018 that specializes in developing a cell bioprocessing platform specifically designed for autologous cell and gene therapy manufacturing. The company offers a microfluidic bioprocessing system that integrates various cell culture capabilities—including seeding, expansion, differentiation, transduction, washing, sorting, concentration, sampling, and harvesting—into a single closed system. This automated technology addresses key challenges in the field, such as process control, scalability, and cost, enabling biologists to efficiently conduct process development by experimenting with multiple cell culture conditions.

Linear Diagnostics develops a proprietary diagnostic platform technology that enables rapid, simultaneous detection of multiple targets using a single reagent. Its core innovation, linear dichroism, facilitates molecular diagnostics tests across various sectors, including infectious diseases and food safety.

AgPlus Diagnostics Ltd. is a UK-based company specializing in the development of diagnostic platform technology aimed at providing quantitative point-of-care (PoC) testing solutions for various clinical applications, including both human and veterinary diagnostics. Founded in 2009 and headquartered in Sharnbrook, the company designs, manufactures, and supplies diagnostic tests and associated readers. AgPlus Diagnostics focuses on creating portable diagnostic devices that utilize electrochemical signaling and measurement systems, enabling healthcare providers to deliver personalized care through rapid and accurate testing. This innovative approach facilitates timely diagnostic results, allowing healthcare professionals to make critical treatment decisions quickly, ultimately benefiting patient outcomes.

Ultromics Limited, founded in 2017 and based in Oxford, United Kingdom, specializes in developing advanced echocardiography software aimed at enhancing the diagnosis of coronary heart disease. By leveraging artificial intelligence, the company has created highly accurate diagnostic tools that improve the identification of coronary artery disease, achieving diagnostic accuracy improvements of over 90%. Ultromics' technology processes complex data from electrocardiograms, empowering healthcare providers to make informed clinical decisions and ultimately enhancing patient care in cardiology.

CHAIN Biotechnology Ltd. is a biotechnology company based in London, United Kingdom, that specializes in harnessing Clostridium bacteria for various applications. Founded in 2014, the company focuses on advancing fermentation processes through synthetic biology and automation, particularly utilizing Clostridium strains to produce chiral chemicals. These chemicals are incorporated into a range of products, including nutraceuticals, personal healthcare items, pharmaceuticals, and fragrances. Notable developments include 3-hydroxybutyrate and (R)-methyl-3HB, a precursor used in glaucoma treatment. CHAIN Biotechnology also aims to create cost-effective fermentation routes from sugar. In addition to its work in fermentation, the company is exploring microbiome therapeutics, developing novel compounds aimed at treating chronic gut-related diseases using its proprietary drug development platform.

Zegami Limited is a company that specializes in visual data exploration, offering a platform designed to assist in analyzing both scientific and medical imaging. Founded in 2015 and headquartered in Oxford, United Kingdom, Zegami's solution integrates media, data, and artificial intelligence to transform visual data into actionable information. The platform enables users to efficiently search, sort, filter, and group large collections of images and associated metadata in real time, facilitating the identification of patterns, correlations, and anomalies within the data. Its applications span various fields, including heating, ventilation, and air conditioning management, microscopy, genomics, plant phenotyping, and cultural heritage institutions such as galleries and museums. Additionally, Zegami's plugin API allows developers to create custom visualizations, enhancing the versatility of their offerings.

HALO X-ray Technologies has been spun out of the Imaging Science Group at Nottingham Trent University and the Cranfield Forensic Institute at Cranfield University. We are developing commercially-focused OEM X-ray diffraction solutions based on novel and patented Focal Construct Technology that provides platform capability across a wide range of application areas. Their initial focus lies in the development of HALO solutions for the aviation security and the medical systems markets. We have strong ties to the aviation sector through a long and prestigious research and development programme that has previously realised novel divergent beam X-ray technology (developed and marketed through various incumbent suppliers such as 3DX-ray Ltd) and kinetic depth systems (developed and marketed through Astrophyscis Inc) as 3rd party solutions. We have a clear focus on medical systems and we are currently part of a consortium recentlly awarded an EPSRC grant on Point-of-Care High Accuracy Fracture Risk Prediction. This is an exciting project and we look forward to working with our partners in developing HALO technology for this market.

Congenica Ltd. is a biotechnology company that specializes in clinical data solutions for genetic diagnosis. Established in 2012 and headquartered in Hinxton, United Kingdom, it offers the Sapientia platform, a clinical genomic analytics tool that integrates human DNA sequences with deep clinical phenotyping. This platform enables clinicians and researchers to interpret genetic diseases and provides actionable insights for diagnosis, prognosis, and research. Additionally, Sapientia supports personalized medicine by facilitating the creation of disease registries, identifying patient populations for clinical studies, and aiding in the discovery of novel drug targets and biomarkers. Congenica's focus is on improving clinical outcomes through advanced genomic analysis.

Oxford Brain Diagnostics develops a Cortical Disarray Measurement platform using MRI scans for clinical research and diagnosis of dementia. It provides an index of brain cellular circuit health, enabling early detection and tracking of dementia progression.

CHAIN Biotechnology Ltd. is a biotechnology company based in London, United Kingdom, that specializes in harnessing Clostridium bacteria for various applications. Founded in 2014, the company focuses on advancing fermentation processes through synthetic biology and automation, particularly utilizing Clostridium strains to produce chiral chemicals. These chemicals are incorporated into a range of products, including nutraceuticals, personal healthcare items, pharmaceuticals, and fragrances. Notable developments include 3-hydroxybutyrate and (R)-methyl-3HB, a precursor used in glaucoma treatment. CHAIN Biotechnology also aims to create cost-effective fermentation routes from sugar. In addition to its work in fermentation, the company is exploring microbiome therapeutics, developing novel compounds aimed at treating chronic gut-related diseases using its proprietary drug development platform.

Ultromics Limited, founded in 2017 and based in Oxford, United Kingdom, specializes in developing advanced echocardiography software aimed at enhancing the diagnosis of coronary heart disease. By leveraging artificial intelligence, the company has created highly accurate diagnostic tools that improve the identification of coronary artery disease, achieving diagnostic accuracy improvements of over 90%. Ultromics' technology processes complex data from electrocardiograms, empowering healthcare providers to make informed clinical decisions and ultimately enhancing patient care in cardiology.

Eagle Genomics is a life sciences software company that provides data management and analytics platforms for genomics and related fields. Its solutions enable management, orchestration and exploitation of genomics and other life sciences data, turning diverse datasets into usable data assets and supporting end-to-end workflows from data integration and curation to analysis, visualization and sharing. The company combines biology, bioinformatics, data science, and enterprise software engineering to help pharmaceutical, consumer goods, and agricultural technology organizations shorten research cycles and improve decision making. Its offerings cover next-generation sequencing data management and analysis, cloud-based bioinformatics, biomarker discovery, microarray analysis, and pipeline design, as well as on-demand consulting and tools for managing research data. Headquartered in Cambridge, United Kingdom, with an international footprint, Eagle Genomics emphasizes building an enterprise information architecture for the genomics era, enabling customers to realize the value of digital assets and enhance productivity across R&D programs.

MIRICO Ltd. is a laser spectroscopy instrumentation company based in Oxford, founded in 2015 as a spin‑out from the STFC Rutherford Appleton Laboratory. It develops high‑performance gas‑sensing products that use laser dispersion, tunable laser absorption, and isotope‑ratio techniques to provide real‑time, in‑situ monitoring of trace gases and isotopologues. The instruments are applied in space exploration, planetary landers, environmental monitoring, atmospheric emissions, geochemistry, medical diagnostics, and oil‑and‑gas exploration and production. The company’s cloud‑connected platform delivers autonomous, continuous measurements in all weather conditions, enabling detection, localisation, and quantification of emissions to support net‑zero targets and operational optimisation.

Procarta Biosystems Ltd is a biotechnology company based in Norwich, United Kingdom, that specializes in the development of innovative DNA-based antibacterials. Founded in 2007 as a spin-out from the John Innes Centre, Procarta focuses on addressing the critical challenge of drug-resistant bacterial strains, commonly referred to as superbugs. The company has created a versatile platform for antibiotic development, which includes proprietary nanoparticles designed to deliver oligonucleotides directly into bacterial pathogens. Their product range features targeted therapies such as MRSA snare, a solution for both topical and intravenous use; Broad-spectrum Gram-negative therapy snare, aimed at treating hospital-acquired infections; and Cdiff snare, which helps prevent the recurrence of Clostridium difficile infections. With a commitment to combating the rising threat of antibiotic resistance, Procarta Biosystems is positioned to enhance therapeutic options in clinical settings.

SFH Oxford Ltd. is a UK-based company specializing in the development and marketing of innovative healthcare products aimed at enhancing the management of venous leg ulcers. Founded in 2011 and located in Didcot, the company has created Graducheck, a sensor-based technology that improves the application of compression bandages, thereby increasing healing rates and promoting patient compliance. SFH Oxford also offers anatomic focus technology graduated compression socks, which provide essential graduated compression, and K-gel wound dressings. The company is actively engaged in clinical and field trials for several of its products, which are showing promising results in real-world applications. With a leadership team experienced in medical device technology, wound care, and business development, SFH Oxford is focused on delivering optimized care for patients and healthcare professionals involved in ulcer management.

Health2Works is a company focused on improving healthcare delivery through digital innovation. It aims to enhance the National Health Service's (NHS) online capabilities by developing applications tailored for patients, caregivers, clinicians, and healthcare managers. By gathering insights from both patients and healthcare professionals, Health2Works rapidly transforms these ideas into proof-of-concept applications that can be tested in real-world settings. The company has created over a dozen applications designed to facilitate patient education and engagement, functioning as a platform for distributing relevant information and measuring its impact. This approach not only streamlines communication between healthcare staff and patients but also empowers users with the information they need to manage their health effectively.

AgPlus Diagnostics Ltd. is a UK-based company specializing in the development of diagnostic platform technology aimed at providing quantitative point-of-care (PoC) testing solutions for various clinical applications, including both human and veterinary diagnostics. Founded in 2009 and headquartered in Sharnbrook, the company designs, manufactures, and supplies diagnostic tests and associated readers. AgPlus Diagnostics focuses on creating portable diagnostic devices that utilize electrochemical signaling and measurement systems, enabling healthcare providers to deliver personalized care through rapid and accurate testing. This innovative approach facilitates timely diagnostic results, allowing healthcare professionals to make critical treatment decisions quickly, ultimately benefiting patient outcomes.

Camtech Diagnostics is pioneering next generation point of care health diagnostics and self testing. Since its inception, the company has successfully brought to market a range of diagnostic tests in biodefence, food safety and Covid self tests during the pandemic

Attomarker is a pioneering health tech company spun out from the University of Exeter. Led by Professor Andrew Shaw, it specializes in patented nanophotonic technology for multiplexed blood testing. The company's flagship product is a CE-marked platform offering rapid, accurate diagnostics via a mobile device, initially focusing on food allergens, pregnancy tests, and infection markers like C-reactive protein.

CHAIN Biotechnology Ltd. is a biotechnology company based in London, United Kingdom, that specializes in harnessing Clostridium bacteria for various applications. Founded in 2014, the company focuses on advancing fermentation processes through synthetic biology and automation, particularly utilizing Clostridium strains to produce chiral chemicals. These chemicals are incorporated into a range of products, including nutraceuticals, personal healthcare items, pharmaceuticals, and fragrances. Notable developments include 3-hydroxybutyrate and (R)-methyl-3HB, a precursor used in glaucoma treatment. CHAIN Biotechnology also aims to create cost-effective fermentation routes from sugar. In addition to its work in fermentation, the company is exploring microbiome therapeutics, developing novel compounds aimed at treating chronic gut-related diseases using its proprietary drug development platform.

AgPlus Diagnostics Ltd. is a UK-based company specializing in the development of diagnostic platform technology aimed at providing quantitative point-of-care (PoC) testing solutions for various clinical applications, including both human and veterinary diagnostics. Founded in 2009 and headquartered in Sharnbrook, the company designs, manufactures, and supplies diagnostic tests and associated readers. AgPlus Diagnostics focuses on creating portable diagnostic devices that utilize electrochemical signaling and measurement systems, enabling healthcare providers to deliver personalized care through rapid and accurate testing. This innovative approach facilitates timely diagnostic results, allowing healthcare professionals to make critical treatment decisions quickly, ultimately benefiting patient outcomes.

Attomarker is a pioneering health tech company spun out from the University of Exeter. Led by Professor Andrew Shaw, it specializes in patented nanophotonic technology for multiplexed blood testing. The company's flagship product is a CE-marked platform offering rapid, accurate diagnostics via a mobile device, initially focusing on food allergens, pregnancy tests, and infection markers like C-reactive protein.

Linear Diagnostics develops a proprietary diagnostic platform technology that enables rapid, simultaneous detection of multiple targets using a single reagent. Its core innovation, linear dichroism, facilitates molecular diagnostics tests across various sectors, including infectious diseases and food safety.

Congenica Ltd. is a biotechnology company that specializes in clinical data solutions for genetic diagnosis. Established in 2012 and headquartered in Hinxton, United Kingdom, it offers the Sapientia platform, a clinical genomic analytics tool that integrates human DNA sequences with deep clinical phenotyping. This platform enables clinicians and researchers to interpret genetic diseases and provides actionable insights for diagnosis, prognosis, and research. Additionally, Sapientia supports personalized medicine by facilitating the creation of disease registries, identifying patient populations for clinical studies, and aiding in the discovery of novel drug targets and biomarkers. Congenica's focus is on improving clinical outcomes through advanced genomic analysis.

Phoenix Health & Safety specializes in delivering health and safety training courses that are accredited by recognized organizations such as IOSH, NEBOSH, ConstructionSkills, and CIEH. The company focuses on providing comprehensive training for individuals responsible for managing health and safety in various settings. Its offerings include both in-person and online courses, which lead to certifications and diplomas. Additionally, Phoenix Health & Safety provides first aid training and electronic learning opportunities, ensuring that students receive relevant qualifications to enhance their career prospects in the health sector. The company boasts a strong commitment to its training effectiveness, guaranteeing a pass for all participants in IOSH and NEBOSH courses.

Eagle Genomics is a life sciences software company that provides data management and analytics platforms for genomics and related fields. Its solutions enable management, orchestration and exploitation of genomics and other life sciences data, turning diverse datasets into usable data assets and supporting end-to-end workflows from data integration and curation to analysis, visualization and sharing. The company combines biology, bioinformatics, data science, and enterprise software engineering to help pharmaceutical, consumer goods, and agricultural technology organizations shorten research cycles and improve decision making. Its offerings cover next-generation sequencing data management and analysis, cloud-based bioinformatics, biomarker discovery, microarray analysis, and pipeline design, as well as on-demand consulting and tools for managing research data. Headquartered in Cambridge, United Kingdom, with an international footprint, Eagle Genomics emphasizes building an enterprise information architecture for the genomics era, enabling customers to realize the value of digital assets and enhance productivity across R&D programs.

AgPlus Diagnostics Ltd. is a UK-based company specializing in the development of diagnostic platform technology aimed at providing quantitative point-of-care (PoC) testing solutions for various clinical applications, including both human and veterinary diagnostics. Founded in 2009 and headquartered in Sharnbrook, the company designs, manufactures, and supplies diagnostic tests and associated readers. AgPlus Diagnostics focuses on creating portable diagnostic devices that utilize electrochemical signaling and measurement systems, enabling healthcare providers to deliver personalized care through rapid and accurate testing. This innovative approach facilitates timely diagnostic results, allowing healthcare professionals to make critical treatment decisions quickly, ultimately benefiting patient outcomes.

Procarta Biosystems Ltd is a biotechnology company based in Norwich, United Kingdom, that specializes in the development of innovative DNA-based antibacterials. Founded in 2007 as a spin-out from the John Innes Centre, Procarta focuses on addressing the critical challenge of drug-resistant bacterial strains, commonly referred to as superbugs. The company has created a versatile platform for antibiotic development, which includes proprietary nanoparticles designed to deliver oligonucleotides directly into bacterial pathogens. Their product range features targeted therapies such as MRSA snare, a solution for both topical and intravenous use; Broad-spectrum Gram-negative therapy snare, aimed at treating hospital-acquired infections; and Cdiff snare, which helps prevent the recurrence of Clostridium difficile infections. With a commitment to combating the rising threat of antibiotic resistance, Procarta Biosystems is positioned to enhance therapeutic options in clinical settings.

MIRICO Ltd. is a laser spectroscopy instrumentation company based in Oxford, founded in 2015 as a spin‑out from the STFC Rutherford Appleton Laboratory. It develops high‑performance gas‑sensing products that use laser dispersion, tunable laser absorption, and isotope‑ratio techniques to provide real‑time, in‑situ monitoring of trace gases and isotopologues. The instruments are applied in space exploration, planetary landers, environmental monitoring, atmospheric emissions, geochemistry, medical diagnostics, and oil‑and‑gas exploration and production. The company’s cloud‑connected platform delivers autonomous, continuous measurements in all weather conditions, enabling detection, localisation, and quantification of emissions to support net‑zero targets and operational optimisation.

Eagle Genomics is a life sciences software company that provides data management and analytics platforms for genomics and related fields. Its solutions enable management, orchestration and exploitation of genomics and other life sciences data, turning diverse datasets into usable data assets and supporting end-to-end workflows from data integration and curation to analysis, visualization and sharing. The company combines biology, bioinformatics, data science, and enterprise software engineering to help pharmaceutical, consumer goods, and agricultural technology organizations shorten research cycles and improve decision making. Its offerings cover next-generation sequencing data management and analysis, cloud-based bioinformatics, biomarker discovery, microarray analysis, and pipeline design, as well as on-demand consulting and tools for managing research data. Headquartered in Cambridge, United Kingdom, with an international footprint, Eagle Genomics emphasizes building an enterprise information architecture for the genomics era, enabling customers to realize the value of digital assets and enhance productivity across R&D programs.

CHAIN Biotechnology Ltd. is a biotechnology company based in London, United Kingdom, that specializes in harnessing Clostridium bacteria for various applications. Founded in 2014, the company focuses on advancing fermentation processes through synthetic biology and automation, particularly utilizing Clostridium strains to produce chiral chemicals. These chemicals are incorporated into a range of products, including nutraceuticals, personal healthcare items, pharmaceuticals, and fragrances. Notable developments include 3-hydroxybutyrate and (R)-methyl-3HB, a precursor used in glaucoma treatment. CHAIN Biotechnology also aims to create cost-effective fermentation routes from sugar. In addition to its work in fermentation, the company is exploring microbiome therapeutics, developing novel compounds aimed at treating chronic gut-related diseases using its proprietary drug development platform.

Health2Works is a company focused on improving healthcare delivery through digital innovation. It aims to enhance the National Health Service's (NHS) online capabilities by developing applications tailored for patients, caregivers, clinicians, and healthcare managers. By gathering insights from both patients and healthcare professionals, Health2Works rapidly transforms these ideas into proof-of-concept applications that can be tested in real-world settings. The company has created over a dozen applications designed to facilitate patient education and engagement, functioning as a platform for distributing relevant information and measuring its impact. This approach not only streamlines communication between healthcare staff and patients but also empowers users with the information they need to manage their health effectively.

Eagle Genomics is a life sciences software company that provides data management and analytics platforms for genomics and related fields. Its solutions enable management, orchestration and exploitation of genomics and other life sciences data, turning diverse datasets into usable data assets and supporting end-to-end workflows from data integration and curation to analysis, visualization and sharing. The company combines biology, bioinformatics, data science, and enterprise software engineering to help pharmaceutical, consumer goods, and agricultural technology organizations shorten research cycles and improve decision making. Its offerings cover next-generation sequencing data management and analysis, cloud-based bioinformatics, biomarker discovery, microarray analysis, and pipeline design, as well as on-demand consulting and tools for managing research data. Headquartered in Cambridge, United Kingdom, with an international footprint, Eagle Genomics emphasizes building an enterprise information architecture for the genomics era, enabling customers to realize the value of digital assets and enhance productivity across R&D programs.

SFH Oxford Ltd. is a UK-based company specializing in the development and marketing of innovative healthcare products aimed at enhancing the management of venous leg ulcers. Founded in 2011 and located in Didcot, the company has created Graducheck, a sensor-based technology that improves the application of compression bandages, thereby increasing healing rates and promoting patient compliance. SFH Oxford also offers anatomic focus technology graduated compression socks, which provide essential graduated compression, and K-gel wound dressings. The company is actively engaged in clinical and field trials for several of its products, which are showing promising results in real-world applications. With a leadership team experienced in medical device technology, wound care, and business development, SFH Oxford is focused on delivering optimized care for patients and healthcare professionals involved in ulcer management.

Phoenix Health & Safety specializes in delivering health and safety training courses that are accredited by recognized organizations such as IOSH, NEBOSH, ConstructionSkills, and CIEH. The company focuses on providing comprehensive training for individuals responsible for managing health and safety in various settings. Its offerings include both in-person and online courses, which lead to certifications and diplomas. Additionally, Phoenix Health & Safety provides first aid training and electronic learning opportunities, ensuring that students receive relevant qualifications to enhance their career prospects in the health sector. The company boasts a strong commitment to its training effectiveness, guaranteeing a pass for all participants in IOSH and NEBOSH courses.

Phoenix Health & Safety specializes in delivering health and safety training courses that are accredited by recognized organizations such as IOSH, NEBOSH, ConstructionSkills, and CIEH. The company focuses on providing comprehensive training for individuals responsible for managing health and safety in various settings. Its offerings include both in-person and online courses, which lead to certifications and diplomas. Additionally, Phoenix Health & Safety provides first aid training and electronic learning opportunities, ensuring that students receive relevant qualifications to enhance their career prospects in the health sector. The company boasts a strong commitment to its training effectiveness, guaranteeing a pass for all participants in IOSH and NEBOSH courses.

Procarta Biosystems Ltd is a biotechnology company based in Norwich, United Kingdom, that specializes in the development of innovative DNA-based antibacterials. Founded in 2007 as a spin-out from the John Innes Centre, Procarta focuses on addressing the critical challenge of drug-resistant bacterial strains, commonly referred to as superbugs. The company has created a versatile platform for antibiotic development, which includes proprietary nanoparticles designed to deliver oligonucleotides directly into bacterial pathogens. Their product range features targeted therapies such as MRSA snare, a solution for both topical and intravenous use; Broad-spectrum Gram-negative therapy snare, aimed at treating hospital-acquired infections; and Cdiff snare, which helps prevent the recurrence of Clostridium difficile infections. With a commitment to combating the rising threat of antibiotic resistance, Procarta Biosystems is positioned to enhance therapeutic options in clinical settings.

ProKyma is a biotechnology company specializing in cell separation technology for enhancing molecular biology tests. Its primary focus is developing an advanced blood test for Circulating Tumour Cells (CTCs), aiming to improve the early detection of cancer metastasis and monitor treatment response across various cancer types. ProKyma's proprietary technology employs high-frequency ultrasound combined with magnetism to manipulate, concentrate, and purify biological cells from complex samples, offering diverse applications in clinical, food safety, environmental, and pharmaceutical sectors. Founded as a spinout from Dstl Porton Down, the company leverages research conducted at this institution to commercialize its innovative separation technologies.

Procarta Biosystems Ltd is a biotechnology company based in Norwich, United Kingdom, that specializes in the development of innovative DNA-based antibacterials. Founded in 2007 as a spin-out from the John Innes Centre, Procarta focuses on addressing the critical challenge of drug-resistant bacterial strains, commonly referred to as superbugs. The company has created a versatile platform for antibiotic development, which includes proprietary nanoparticles designed to deliver oligonucleotides directly into bacterial pathogens. Their product range features targeted therapies such as MRSA snare, a solution for both topical and intravenous use; Broad-spectrum Gram-negative therapy snare, aimed at treating hospital-acquired infections; and Cdiff snare, which helps prevent the recurrence of Clostridium difficile infections. With a commitment to combating the rising threat of antibiotic resistance, Procarta Biosystems is positioned to enhance therapeutic options in clinical settings.

ProKyma is a biotechnology company specializing in cell separation technology for enhancing molecular biology tests. Its primary focus is developing an advanced blood test for Circulating Tumour Cells (CTCs), aiming to improve the early detection of cancer metastasis and monitor treatment response across various cancer types. ProKyma's proprietary technology employs high-frequency ultrasound combined with magnetism to manipulate, concentrate, and purify biological cells from complex samples, offering diverse applications in clinical, food safety, environmental, and pharmaceutical sectors. Founded as a spinout from Dstl Porton Down, the company leverages research conducted at this institution to commercialize its innovative separation technologies.

Procarta Biosystems Ltd is a biotechnology company based in Norwich, United Kingdom, that specializes in the development of innovative DNA-based antibacterials. Founded in 2007 as a spin-out from the John Innes Centre, Procarta focuses on addressing the critical challenge of drug-resistant bacterial strains, commonly referred to as superbugs. The company has created a versatile platform for antibiotic development, which includes proprietary nanoparticles designed to deliver oligonucleotides directly into bacterial pathogens. Their product range features targeted therapies such as MRSA snare, a solution for both topical and intravenous use; Broad-spectrum Gram-negative therapy snare, aimed at treating hospital-acquired infections; and Cdiff snare, which helps prevent the recurrence of Clostridium difficile infections. With a commitment to combating the rising threat of antibiotic resistance, Procarta Biosystems is positioned to enhance therapeutic options in clinical settings.

ProKyma is a biotechnology company specializing in cell separation technology for enhancing molecular biology tests. Its primary focus is developing an advanced blood test for Circulating Tumour Cells (CTCs), aiming to improve the early detection of cancer metastasis and monitor treatment response across various cancer types. ProKyma's proprietary technology employs high-frequency ultrasound combined with magnetism to manipulate, concentrate, and purify biological cells from complex samples, offering diverse applications in clinical, food safety, environmental, and pharmaceutical sectors. Founded as a spinout from Dstl Porton Down, the company leverages research conducted at this institution to commercialize its innovative separation technologies.